FDA to discuss easing restrictions on peptides despite safety concerns
•Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacyAdvisers to the Food and Drug Administration (FDA) will soon hold a meeting about...
هذا الخبر من The Guardian World. خبر يقدم أدوات ذكاء اصطناعي للتلخيص والترجمة والاستماع.
المصدر: The Guardian World | Source: The Guardian WorldCommittee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy
Advisers to the Food and Drug Administration (FDA) will soon hold a meeting about whether to ease restrictions on access to some research peptides, a group of drugs with a zealous following and thin evidence to support them.
If restrictions are eased, US compounding pharmacies would be able to produce and fill prescriptions for Americans – a change that would effectively legalize a thriving gray market.
Continue reading...
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة The Guardian World. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by The Guardian World. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
